Literature DB >> 22383790

Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.

Yasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, Luis E Fayad, Michelle Fanale, Jorge Romaguera, Anas Younes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22383790     DOI： 10.1182/blood-2011-11-391037

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  22 in total

Review 1.  Why anti-Bcl-2 clinical trials fail: a solution.

Authors:  Y Harazono; K Nakajima; A Raz
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

Review 2.  Bcl-2 antagonists: a proof of concept for CLL therapy.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Invest New Drugs       Date:  2013-08-02       Impact factor: 3.850

3.  Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites.

Authors:  Alyse N Douglass; Heather S Kain; Marian Abdullahi; Nadia Arang; Laura S Austin; Sebastian A Mikolajczak; Zachary P Billman; Jen C C Hume; Sean C Murphy; Stefan H I Kappe; Alexis Kaushansky
Journal:  Mol Ther       Date:  2015-02-04       Impact factor: 11.454

Review 4.  Targeting the apoptosis pathway in hematologic malignancies.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2014-02-04

5.  Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

Authors:  Alberto Chiappori; Charles Williams; Donald W Northfelt; John W Adams; Shakun Malik; Martin J Edelman; Peter Rosen; David A Van Echo; Mark S Berger; Eric B Haura
Journal:  J Thorac Oncol       Date:  2014-01       Impact factor: 15.609

Review 6.  Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

Authors:  Ruifang Sun; Jinfen Wang; Ken H Young
Journal:  Crit Rev Oncog       Date:  2017

Review 7.  Hematologic malignancies: newer strategies to counter the BCL-2 protein.

Authors:  Abdul Shukkur Ebrahim; Hussam Sabbagh; Allison Liddane; Ali Raufi; Mustapha Kandouz; Ayad Al-Katib
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-04       Impact factor: 4.553

Review 8.  Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?

Authors:  K Brinkmann; H Kashkar
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

9.  Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors.

Authors:  Qiang Liu; Hong-Gang Wang
Journal:  Commun Integr Biol       Date:  2012-11-01

10.  An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies.

Authors:  Carolyn A Goard; Aaron D Schimmer
Journal:  Core Evid       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.